$-0.20 EPS Expected for Sangamo Therapeutics Inc (SGMO)

October 12, 2017 - By Michael Collier

 $ 0.20 EPS Expected for Sangamo Therapeutics Inc (SGMO)
Investors sentiment increased to 1.59 in 2017 Q2. Its up 0.79, from 0.8 in 2017Q1. It is positive, as 13 investors sold Sangamo Therapeutics Inc shares while 31 reduced holdings. 33 funds opened positions while 37 raised stakes. 50.83 million shares or 24.82% more from 40.72 million shares in 2017Q1 were reported.
First Mercantile Trust invested in 0.01% or 4,687 shares. Leisure Cap Management holds 0.32% or 40,541 shares in its portfolio. Moreover, Dafna Cap Management Llc has 1.41% invested in Sangamo Therapeutics Inc (NASDAQ:SGMO). Creative Planning has invested 0% in Sangamo Therapeutics Inc (NASDAQ:SGMO). Granahan Investment Mngmt Ma stated it has 0.57% in Sangamo Therapeutics Inc (NASDAQ:SGMO). 727,615 are held by Geode Capital Management Ltd Liability Corporation. Highlander Mgmt Ltd Liability Co reported 14,000 shares. Sanctuary Wealth Ltd Liability Corp reported 1,001 shares. Voya Lc holds 0% of its portfolio in Sangamo Therapeutics Inc (NASDAQ:SGMO) for 33,809 shares. Federated Investors Pa holds 0% in Sangamo Therapeutics Inc (NASDAQ:SGMO) or 148,211 shares. Fic Cap holds 3.48% of its portfolio in Sangamo Therapeutics Inc (NASDAQ:SGMO) for 960,338 shares. Cubist Systematic Strategies Lc invested 0% of its portfolio in Sangamo Therapeutics Inc (NASDAQ:SGMO). Alliancebernstein L P has invested 0% of its portfolio in Sangamo Therapeutics Inc (NASDAQ:SGMO). Commercial Bank Of Mellon Corporation stated it has 0% in Sangamo Therapeutics Inc (NASDAQ:SGMO). Hudson Bay Capital Management Lp accumulated 45,000 shares.

Since May 11, 2017, it had 0 insider purchases, and 2 insider sales for $34,754 activity.

Analysts expect Sangamo Therapeutics Inc (NASDAQ:SGMO) to report $-0.20 EPS on October, 25.They anticipate $0.07 EPS change or 25.93 % from last quarter’s $-0.27 EPS. After having $-0.17 EPS previously, Sangamo Therapeutics Inc’s analysts see 17.65 % EPS growth. The stock increased 1.57% or $0.25 during the last trading session, reaching $16.15. About shares traded. Sangamo Therapeutics Inc (NASDAQ:SGMO) has risen 29.78% since October 12, 2016 and is uptrending. It has outperformed by 13.08% the S&P500.

Sangamo Therapeutics Inc (NASDAQ:SGMO) Ratings Coverage

Among 9 analysts covering Sangamo Biosciences (NASDAQ:SGMO), 4 have Buy rating, 1 Sell and 4 Hold. Therefore 44% are positive. Sangamo Biosciences has $22 highest and $4 lowest target. $13’s average target is -19.50% below currents $16.15 stock price. Sangamo Biosciences had 16 analyst reports since August 8, 2015 according to SRatingsIntel. Piper Jaffray downgraded Sangamo Therapeutics Inc (NASDAQ:SGMO) on Wednesday, October 19 to “Neutral” rating. Jefferies maintained Sangamo Therapeutics Inc (NASDAQ:SGMO) on Wednesday, September 2 with “Buy” rating. The company was reinitiated on Thursday, June 22 by Jefferies. On Tuesday, September 8 the stock rating was downgraded by Zacks to “Sell”. The stock has “Buy” rating by JP Morgan on Thursday, September 3. Jefferies reinitiated the shares of SGMO in report on Friday, October 23 with “Buy” rating. The firm has “Hold” rating given on Thursday, August 10 by Piper Jaffray. The rating was downgraded by PiperJaffray on Wednesday, October 19 to “Neutral”. The firm has “Buy” rating given on Tuesday, September 12 by Jefferies. The company was initiated on Friday, December 4 by Wells Fargo.

Sangamo Therapeutics, Inc., formerly Sangamo BioSciences, Inc., is a clinical-stage biotechnology company. The company has market cap of $1.35 billion. The Firm is focused on translating science into genomic therapies that transform patients’ lives using the Company’s platform technologies in genome editing, gene therapy, gene regulation and cell therapy. It currently has negative earnings. The Firm has clinical and preclinical programs in development and partnered certain programs with biopharmaceutical companies to expedite clinical and commercial development.

More news for Sangamo Therapeutics Inc (NASDAQ:SGMO) were recently published by: Prnewswire.com, which released: “Sangamo Therapeutics Announces Presentation At The 2017 Cantor Fitzgerald …” on September 20, 2017. Prnewswire.com‘s article titled: “Sangamo Therapeutics Announces Participation At Upcoming Investor And Industry …” and published on September 28, 2017 is yet another important article.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Twitter Auto Publish Powered By : XYZScripts.com